Drug Profile
INOC 002
Alternative Names: BIO 117; INOC002Latest Information Update: 16 Mar 2009
Price :
$50
*
At a glance
- Originator Avantogen Oncology
- Class Antineoplastics
- Mechanism of Action Immunomodulators; Phosphoric monoester hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 01 Jun 2006 Innovate Oncology is now a wholly owned subsidiary of Avantogen
- 30 May 2006 Innovate Oncology has been acquired by Avantogen
- 16 Sep 2005 Phase-II clinical trials in Colorectal cancer in USA (unspecified route)